Dr. Josh Silverman is a serial biotechnology entrepreneur and executive with more than two decades of experience leading research-driven companies from early science to commercial impact. He is the Founder and Chief Executive Officer of Windfall Bio, and has previously founded, led, or held senior executive roles at Aromyx, Calysta, Siluria, Amunix, Avidia, Amgen, and Maxygen. Collectively, the ventures he has founded or led have raised more than $300M in equity financing and produced over $1.7B in cumulative exit value.

Josh's expertise spans the full arc of biotech leadership: scientific strategy, R&D management, platform and product development, machine learning and AI applications, regulatory and clinical pathways, fundraising, corporate and government partnerships, intellectual property, and commercialization. Across his career, he has helped bring three novel biopharmaceuticals from early-stage research into clinical trials, as well as developing the technology leading to construction of two commercial-scale production facilities.

Josh holds a Ph.D. in Biochemistry from Stanford University and a B.S. in Molecular Biology from UC San Diego. He is a named inventor on more than 90 issued and pending patents, a published author in journals including Nature Biotechnology, an advisor to multiple biotech and startup companies, and a frequent speaker on biotechnology, sustainability, and the commercialization of science.